PTC Therapeutics Inc Earnings

The next earnings date for PTC Therapeutics Inc is February 24, 2026.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of PTC Therapeutics Inc Earnings

Report DateEstimated Earnings Per Share
02/24/2026$-0.91

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

PTC Therapeutics Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
10/23/2025---$0100.00%
08/07/2025---$-0.8321.70%
04/23/2025Before Market$10.041,524.11%
02/26/2025After Market$-0.3447.45%
11/07/2024After Market$-1.393.47%
08/08/2024After Market$-1.27-20.95%
04/25/2024After Market$-1.203.23%
02/29/2024After Market$-0.24-148.00%
10/26/2023After Market$-1.76-50.43%
08/03/2023After Market$-2.66-55.56%
04/27/2023After Market$-1.88-23.68%
02/21/2023After Market$-1.89-18.87%
10/27/2022After Market$-1.53-23.39%
08/04/2022After Market$-2.13-60.15%
05/03/2022After Market$-1.78-17.88%
02/22/2022After Market$-2.03-23.03%
10/28/2021After Market$-1.89-26.85%
07/29/2021After Market$-1.687.69%
05/04/2021After Market$-1.83-21.19%
02/25/2021After Market$-1.08-14.89%
10/29/2020After Market$-1.03-1,616.67%
08/05/2020After Market$-2.62-101.54%
04/30/2020After Market$-1.81-36.09%
03/02/2020After Market$-1.37-168.63%
10/29/2019After Market$-1.06-39.47%
08/06/2019After Market$-0.75-29.31%
05/02/2019After Market$-1.29-69.74%
02/28/2019After Market$-0.58-81.25%
11/05/2018After Market$-1.06-165.00%
08/07/2018After Market$-0.2127.59%
05/09/2018After Market$-0.46-6.98%
03/06/2018After Market$0.03121.43%
11/02/2017After Market$-0.82-20.59%
08/08/2017After Market$-0.4465.63%
05/08/2017Before Market$-0.8517.48%
03/16/2017Before Market$-0.7827.10%
11/02/2016After Market$-1.0315.57%
08/04/2016After Market$-1.1410.24%
05/05/2016After Market$-1.223.17%
02/29/2016After Market$-1.50-20.97%
11/09/2015After Market$-1.27-10.43%
07/30/2015After Market$-1.145.00%
05/04/2015After Market$-1.154.17%
02/27/2015Before Market$-0.84-2.44%
11/06/2014Before Market$-0.93-3.33%
08/07/2014---$-0.86-16.22%
05/06/2014---$-0.58-26.09%
03/06/2014---$-0.75-31.58%
11/14/2013---$-0.1936.67%
08/12/2013---$-5.51-615.58%

More About PTC Therapeutics Inc

Website
https://www.ptcbio.com
Country
USA
Full Time Employees
939

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

“PTC Therapeutics Inc Earnings” Can Refer to the PTC Therapeutics Inc Earnings Date

Some people say “PTC Therapeutics Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my PTC Therapeutics Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning PTC Therapeutics Inc Stock on the Earnings Date

If you own PTC Therapeutics Inc stock (PTCT) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for PTC Therapeutics Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading PTC Therapeutics Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More PTC Therapeutics Inc Earnings

You can contact us any time if you would like to ask questions about PTC Therapeutics Inc earnings or anything else related to the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.